Quantinno Capital Management LP Sells 98,466 Shares of Organon & Co. $OGN

Quantinno Capital Management LP decreased its position in Organon & Co. (NYSE:OGN) by 27.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 265,024 shares of the company’s stock after selling 98,466 shares during the quarter. Quantinno Capital Management LP owned approximately 0.10% of Organon & Co. worth $1,587,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. AQR Capital Management LLC raised its holdings in shares of Organon & Co. by 105.2% in the fourth quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock valued at $61,282,000 after purchasing an additional 4,394,814 shares during the last quarter. UBS Group AG boosted its holdings in Organon & Co. by 55.2% during the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock worth $30,795,000 after purchasing an additional 1,527,492 shares during the last quarter. First Trust Advisors LP grew its position in Organon & Co. by 78.1% in the 1st quarter. First Trust Advisors LP now owns 3,227,320 shares of the company’s stock worth $19,332,000 after purchasing an additional 1,415,239 shares in the last quarter. Private Management Group Inc. grew its position in Organon & Co. by 38.3% in the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock worth $31,169,000 after purchasing an additional 1,204,979 shares in the last quarter. Finally, Balyasny Asset Management L.P. increased its stake in Organon & Co. by 102.1% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company’s stock valued at $23,925,000 after buying an additional 1,131,941 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. BNP Paribas Exane reissued a “neutral” rating and set a $14.00 target price (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Weiss Ratings downgraded Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Finally, Piper Sandler upgraded Organon & Co. from an “underweight” rating to a “neutral” rating and lifted their price target for the stock from $5.00 to $14.00 in a report on Tuesday, April 28th. Five equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Organon & Co. currently has an average rating of “Reduce” and a consensus target price of $11.40.

Organon & Co. Trading Up 0.1%

Shares of OGN stock opened at $13.66 on Thursday. The company has a 50 day moving average of $13.51 and a 200-day moving average of $10.68. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.70. The firm has a market cap of $3.59 billion, a P/E ratio of 17.74, a PEG ratio of 1.26 and a beta of 1.55.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Organon & Co.’s dividend payout ratio is currently 10.39%.

Organon & Co. Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.